{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+With+Systemic+Sclerosis&page=2",
    "query": {
      "condition": "Interstitial Lung Disease With Systemic Sclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+With+Systemic+Sclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:18:07.058Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06329401",
      "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "Progressive Pulmonary Fibrosis",
        "Pulmonary Fibrosis Secondary to Systemic Sclerosis",
        "Pulmonary Fibrosis, Interstitial Lung Disease",
        "Interstitial Lung Disease",
        "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",
        "Interstitial Lung Disease in Patients With Rheumatoid Arthritis",
        "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere",
        "Hypersensitivity Pneumonitis",
        "Interstitial Lung Disease With Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Avalyn Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-04-03",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329401"
    },
    {
      "nct_id": "NCT04837131",
      "title": "A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma",
        "Diffuse Systemic Sclerosis",
        "Diffuse Scleroderma",
        "Diffuse Cutaneous Systemic Sclerosis",
        "Diffuse Cutaneous Scleroderma",
        "Progressive Systemic Sclerosis",
        "Progressive Scleroderma",
        "Scleroderma, Systemic",
        "Scleroderma, Diffuse",
        "Scleroderma;Progressive",
        "Systemic Sclerosis, Diffuse",
        "Systemic; Sclerosis, Progressive",
        "Scleroderma of Lung",
        "Scleroderma With Pulmonary Involvement",
        "Systemic Sclerosis Pulmonary",
        "Systemic Sclerosis With Lung Involvement",
        "Interstitial Lung Disease",
        "Pulmonary Fibrosis Interstitial"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael M. Pham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-04-28",
      "completion_date": "2024-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837131"
    },
    {
      "nct_id": "NCT01559129",
      "title": "Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic",
        "Sclerosis, Systemic",
        "Systemic Scleroderma",
        "Systemic Sclerosis",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Pomalidomide (CC-4047)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2012-08-09",
      "completion_date": "2016-11-03",
      "has_results": true,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01559129"
    },
    {
      "nct_id": "NCT02745145",
      "title": "Abituzumab in SSc-ILD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis-associated Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Abituzumab 1500 mg",
          "type": "DRUG"
        },
        {
          "name": "Abituzumab 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-05-31",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02745145"
    },
    {
      "nct_id": "NCT05270668",
      "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Companion diagnostic ( CDx)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2022-03-29",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270668"
    },
    {
      "nct_id": "NCT06716606",
      "title": "A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Connective Tissue Diseases"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2024-12-12",
      "completion_date": "2029-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06716606"
    },
    {
      "nct_id": "NCT03840928",
      "title": "PatientSpot Formerly Known as ArthritisPower",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis",
        "Ankylosing Spondylitis",
        "Fibromyalgia",
        "Gout",
        "Crohn Disease",
        "Juvenile Idiopathic Arthritis",
        "Lupus Erythematosus",
        "Myositis",
        "Osteoarthritis",
        "Osteoporosis",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Scleroderma",
        "Dermatomyositis",
        "Inflammatory Bowel Diseases",
        "Polymyositis",
        "Axial Spondyloarthritis",
        "Diffuse Idiopathic Skeletal Hyperostosis",
        "Polymyalgia Rheumatica",
        "Giant Cell Arteritis",
        "Temporal Arteritis",
        "Wegener",
        "Relapsing Polychondritis",
        "Undifferentiated Connective Tissue Disease",
        "Spinal Cord Injuries",
        "Alzheimer Disease",
        "Amyotrophic Lateral Sclerosis",
        "Ataxia",
        "Bell Palsy",
        "Brain Tumor",
        "Cerebral Aneurysm",
        "Epilepsy",
        "Guillain-Barre Syndrome",
        "Headache",
        "Head Injury",
        "Hydrocephalus",
        "Lumbar Disc Disease",
        "Meningitis",
        "Multiple Sclerosis",
        "Muscular Dystrophy",
        "Neurocutaneous Syndromes",
        "Parkinson Disease",
        "Stroke",
        "Cluster Headache",
        "Tension-Type Headache",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Lung Cancer",
        "Cystic Fibrosis",
        "Sleep Apnea",
        "Eczema",
        "Alopecia",
        "Chronic Inflammation",
        "Unstable Angina",
        "Heart Attack",
        "Heart Failure",
        "Arrythmia",
        "Valve Heart Disease",
        "High Blood Pressure",
        "Congenital Heart Disease",
        "Peripheral Arterial Disease",
        "Diabetes",
        "Chronic Liver Disease",
        "Obesity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Global Healthy Living Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40000,
      "start_date": "2015-04-01",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 1,
      "location_summary": "Upper Nyack, New York",
      "locations": [
        {
          "city": "Upper Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840928"
    },
    {
      "nct_id": "NCT03630211",
      "title": "Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Diffuse Sclerosis Systemic",
        "Interstitial Lung Disease",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Anti Thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "8 Years to 60 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-07-31",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630211"
    },
    {
      "nct_id": "NCT05925803",
      "title": "Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Anifrolumab (blinded)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo (blinded)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab (unblinded, open label)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 314,
      "start_date": "2023-11-08",
      "completion_date": "2028-04-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05925803"
    },
    {
      "nct_id": "NCT07047690",
      "title": "A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2026-02-20",
      "completion_date": "2028-07-23",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-06-10T15:18:07.058Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Arlington, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07047690"
    }
  ]
}